pentobarbital will decrease the level or outcome of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
buprenorphine subdermal implant and pentobarbital each improve sedation. Prevent or Use Alternate Drug. Limit use to individuals for whom option treatment method options are insufficient
pentobarbital will minimize the extent or result of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.
pentobarbital will decrease the level or influence of lapatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will lower the level or outcome of conjugated estrogens by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
Contraindicated (one)pentobarbital will minimize the level or result of dienogest/estradiol valerate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Women of all ages mustn't opt for estradiol valerate/dienogest as their contraceptive when employing powerful CYP3A4 inducers as a result of prospective reduce in contraceptive efficacy.
When the dose in the concomitant CYP3A4 inducer can't be lessened or discontinued, implant removal can be required and the individual should then be handled with a buprenorphine dosage kind that allows dose changes. If a CYP3A4 inducer is discontinued in the patient who is stabilized on buprenorphine, keep an eye on the affected individual for overmedication.
This drug may perhaps interfere Along with the absorption of orally administered griseofulvin, lowering its blood levels; results of blood stage reduction not known; preferable to prevent concomitant administration of these medicine
pentobarbital will minimize the level or outcome of etoposide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will lower the level or result of parecoxib by influencing hepatic 戊巴比妥鈉製作 enzyme CYP2C9/ten metabolism. Use Caution/Watch.
pentobarbital will minimize the level or impact of cannabidiol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Contemplate a rise in cannabidiol dosage (dependant on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer.
pentobarbital will decrease the extent or outcome of buprenorphine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
Monitor Closely (1)pentobarbital will decrease the level or effect of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Use of alternative remedies is strongly suggested when linagliptin is always to be administered using a CYP3A4 inducer
pentobarbital will minimize the extent or outcome of glecaprevir/pibrentasvir by influencing hepatic/intestinal enzyme CYP3A4 metabolism.